Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)

Regression Models and Life-Tables

Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793

Nonparametric Estimation from Incomplete Observations

Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158

Regularization Paths for Generalized Linear Models via Coordinate Descent

Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927

On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other

Mann, H. B., & Whitney, D. R. (1947) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177730491 · Cited by 14,320

Evaluation of survival data and two new rank order statistics arising in its consideration.

Mantel, N. (1966) · PubMed · Cited by 7,516

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170

Colorectal cancer statistics, 2017

Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807

Cancer treatment and survivorship statistics, 2012

Siegel, R. L., Desantis, C. E., Virgo, K. S., Stein, K., Mariotto, A. B., Smith, T. G., Cooper, D. L., Gansler, T. S., Lerro, C. C., Fedewa, S. A., et al. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,979

Cancer treatment and survivorship statistics, 2014

Desantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,847

FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

Stahler, A., Hoppe, B., Na, I.-K., Keilholz, L., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., Fischer von Weikersthal, L., Goekkurt, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02582 · Cited by 16

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

Niogret, J., Limagne, E., Thibaudin, M., Blanc, J., Bertaut, A., Malicot, K. L., Rinaldi, Y., Caroli‐Bosc, F., Audemar, F., Nguyen, S., et al. (2020) · Cancers · doi:10.3390/cancers12061429 · Cited by 16

A novel epithelial‐mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer

Shan, Z., Wu, W., Yan, X., Yang, Y. P., Luo, D., Liu, Q., Li, X., Goel, A., & Ma, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16387 · Cited by 15

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations

Innocenti, F., Mu, W., Qu, X., Ou, F., Kabbarah, O., Blanke, C. D., Venook, A. P., Lenz, H., & Rashid, N. U. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00825 · Cited by 15

Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)

Snyder, R. A., He, J., Le‐Rademacher, J. G., Ou, F., Dodge, A., Zemla, T., Paskett, E. D., Chang, G. J., Innocenti, F., Blanke, C. D., et al. (2021) · Cancer · doi:10.1002/cncr.33649 · Cited by 15

Type I and II interferon signaling in colorectal cancer liver metastasis

Mödl, B., Moritsch, S., Zwolanek, D., & Eferl, R. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156075 · Cited by 18

Early-onset colorectal cancer research: gaps and opportunities

Brockway-Lunardi, L., Nelson, S. A., Pandiri, A. R., Tricoli, J. V., Umar, A., Wali, A., & Daschner, P. J. (2020) · Colorectal Cancer · doi:10.2217/crc-2020-0028 · Cited by 14

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas

Sànchez‐Tilló, E., Pedrosa, L., Vila, I., Chen, Y., Győrffy, B., Sánchez-Moral, L., Siles, L., Lozano, J. J., Esteve‐Codina, A., Darling, D. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164629 · Cited by 13

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial

Suenaga, M., Stintzing, S., Cao, S., Zhang, W., Yang, D., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Schirripa, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.019 · Cited by 14

Stromal Signals Dominate Gene Expression Signature Scores That Aim to Describe Cancer Cell–intrinsic Stemness or Mesenchymality Characteristics

Kreis, J., Aybey, B., Geist, F., Brors, B., & Staub, E. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0383 · Cited by 13

Seed and Soil: Consensus Molecular Subgroups (CMS) and Tumor Microenvironment Features Between Primary Lesions and Metastases of Different Organ Sites in Colorectal Cancer

Luo, Q., Quan, Y., Liu, W., Wu, Z., Qiu, W., Liang, W., Yang, P., Huang, Q., Li, G., Wei, J., et al. (2024) · Cancer Management and Research · doi:10.2147/cmar.s441675 · Cited by 13

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer

Wang, L., Liu, Y., Yin, X., Fang, W. J., Xiong, J., Zhao, B., Zhang, M., Zou, Y., Qiu, H., & Yuan, X. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11036 · Cited by 13

Systems analysis of protein signatures predicting cetuximab responses in KRAS , NRAS , BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer

Lindner, A. U., Carberry, S., Monsefi, N., Barat, A., Salvucci, M., O’Byrne, R., Zanella, E. R., Cremona, M., Hennessy, B. T., Bertotti, A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33226 · Cited by 12

CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II–III colorectal carcinoma

Brunac, A., Fourquet, J., Pérot, G., Jaffrelot, M., Meilleroux, J., Danjoux, M., Filleron, T., Nicolaï, V., Guimbaud, R., Icher, S., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01166-9 · Cited by 13

Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma

Ignatova, E., Kozlov, E. M., Ivanov, M. V., Mileyko, V., Menshikova, S., Sun, H., Fedyanin, M. Y., Tryakin, A. A., & Stilidi, I. S. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i3.628 · Cited by 12

Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer

Chowdhury, S., Gupta, R., Millstein, J., Lin, K., Haridas, V., Zeineddine, M. A. A., Parseghian, C. M., Lenz, H., Kopetz, S., & Shen, J. P. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00422 · Cited by 11

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study

Marques, R. P., Godinho, A. R., Heudtlass, P., Pais, H. L., Quintela, A., & Martins, A. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03167-0 · Cited by 12

Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer

van der Heide, D. M., Turaga, K. K., Chan, C. H. F., & Sherman, S. K. (2021) · Journal of Surgical Research · doi:10.1016/j.jss.2021.03.040 · Cited by 13

Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review)

Sultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11

Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients

Oliveres, H., Pesántez, D., & Maurel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095019 · Cited by 11

Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade

He, L., Jin, M., Jian, D., Yang, B., Dai, N., Feng, Y., He, X., & Wang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955187 · Cited by 11

Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL

Kumbrink, J., Bohlmann, L., Mamlouk, S., Redmer, T., Peilstöcker, D., Li, P., Lorenzen, S., Algül, H., Kasper, S., Hempel, D., et al. (2022) · Cancers · doi:10.3390/cancers14153631 · Cited by 10

A prognostic six‐gene expression risk‐score derived from proteomic profiling of the metastatic colorectal cancer secretome

Robles, J., Pintado‐Berninches, L., Boukich, I., Escudero, B., Rı́os, V. D. L., Bartolomé, R. A., Jaén, M., Martín‐Regalado, Á., Fernández‐Aceñero, M. J., Imbaud, J. I., et al. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.294 · Cited by 12

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component

Zhou, Y., Long, Y., Chen, Y., Liu, J., Pu, D., Huang, J., Bi, F., Li, Q., Gou, H., & Qiu, M. (2021) · Cancer Medicine · doi:10.1002/cam4.3876 · Cited by 10

Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer

Song, K., Cai, H., Zheng, H., Yang, J., Jin, L., Xiao, H., Zhang, J., Zhao, Z., Li, X., Zhao, W., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab077 · Cited by 10

Omics technologies as powerful approaches to unravel colorectal cancer complexity and improve its management

Fatfat, Z., Hussein, M. M., Fatfat, M., & Gali‐Muhtasib, H. U. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100200 · Cited by 10

Prediction of long-term recurrence-free and overall survival in early-onset colorectal cancer: the ENCORE multi-centre study

Mannucci, A., Hernández, G., Uetake, H., Yamada, Y., Balaguer, F., Baba, H., Chen, T., Chen, J., Boland, C. R., Cavestro, G. M., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00978-7 · Cited by 9

Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

Paz-Cabezas, M., Calvo-López, T., Romera-López, A., Tabas‐Madrid, D., Ogando, J., Fernández‐Aceñero, M. J., Sastre, J., Pascual-Montano, A., Mañes, S., Díaz‐Rubio, E., et al. (2022) · Cancers · doi:10.3390/cancers14215175 · Cited by 9

Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor

Alburquerque-González, B., López-Calderón, F., López-Abellán, M. D., Esteban-Gil, Á., García‐Solano, J., & Conesa‐Zamora, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061991 · Cited by 9

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC

Jin, H., Amonkar, M. M., Aguiar‐Ibáñez, R., Thosar, M., Chase, M., & Keeping, S. (2022) · Future Oncology · doi:10.2217/fon-2021-1633 · Cited by 9

Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?

Nyamundanda, G., Fontana, E., & Sadanandam, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz294 · Cited by 9

Prognostic and Predictive Value of SARIFA-status Within Molecular Subgroups of Colorectal Cancer

Reitsam, N. G., Offermans, K., Simons, C. C. J. M., Grosser, B., Zimmermann, J., Grabsch, H. I., Märkl, B., & van den Brandt, P. A. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002408 · Cited by 8

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)

Stahler, A., Heinemann, V., Schuster, V., Heinrich, K., Kurreck, A., Gießen-Jung, C., von Weikersthal, L. F., Kaiser, F., Decker, T. W., Held, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.017 · Cited by 8

Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis

Greene, M. W., Abraham, P., Kuhlers, P. C., Lipke, E. A., Heslin, M. J., Wijaya, S. T., & Odeniyi, I. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268436 · Cited by 10

Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives

Battaglin, F., Puccini, A., Naseem, M., Schirripa, M., Berger, M. D., Tokunaga, R., McSkane, M., Khoukaz, T., Soni, S., Zhang, W., et al. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.04 · Cited by 8

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma

Rachiglio, A. M., Sacco, A., Forgione, L., Esposito, C., Chicchinelli, N., & Normanno, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00004 · Cited by 9

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

Yazdani, A., Lenz, H., Pillonetto, G., Méndez-Giráldez, R., Yazdani, A., Sanoff, H. K., Hadi, R., Samiei, E., Venook, A. P., Ratain, M. J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-024-00728-z · Cited by 11

Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Rojas, M., Manzi, M., Madurga, S., Velásquez, F. E. G., Romero, M. A., Marín, S., Cascante, M., & Maurel, J. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002337 · Cited by 7

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer

Takahashi, S. I., Sakamoto, Y., Denda, T., Takashima, A., Komatsu, Y., Nakamura, M., Ohori, H., Yamaguchi, T., Kobayashi, Y., Baba, H., et al. (2021) · Cancer Science · doi:10.1111/cas.14841 · Cited by 7

The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy

Yang, Y.-R., Shi, C., Chang, S., Wu, Y.-Y., Su, Y., Lin, G., & Kuan, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-33439-x · Cited by 7

Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer

Lu, Y., Gu, D., Zhao, C., Sun, Y., Li, W., He, L., Wang, X., Kou, Z., Jiang, S., & Guo, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160052 · Cited by 7

KRAS, NRAS, and BRAF Hot-Spot Mutations in Relation to Sidedness of Primary Colorectal Cancer: A Retrospective Cohort Study

Abdelgadir, O., Kuo, Y., Okorodudu, A. O., Khan, M. F., Cheng, Y., & Dong, J. (2025) · Diagnostics · doi:10.3390/diagnostics15020142 · Cited by 6

Cost-effective screening using a two-antibody panel for detecting mismatch repair deficiency in sporadic colorectal cancer

Kim, J. B., Kim, Y., Yoon, Y. S., Kim, J., Park, S. Y., Lee, J. L., Kim, C. W., Park, I. J., Lim, S., Yu, C. S., et al. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i24.6999 · Cited by 6

p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy

Kumbrink, J., Li, P., Pók-Udvari, Á., Klauschen, F., Kirchner, T., & Jung, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212364 · Cited by 6

A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities

López‐Camacho, E., Prado-Vázquez, G., Martínez-Pérez, D., Ferrer-Gómez, M., Llorente-Armijo, S., López‐Vacas, R., Díaz‐Almirón, M., Gámez‐Pozo, A., Vara, J. Á. F., Feliú, J., et al. (2023) · Cancers · doi:10.3390/cancers15041104 · Cited by 6

Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer

Diehl, T. M., & Abbott, D. E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00878-5 · Cited by 6

Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy

Wu, X., Ye, Y., Vega, K. J., & Yao, J. (2022) · Cancers · doi:10.3390/cancers14153740 · Cited by 6

Personalized treatment using predictive biomarkers in solid organ malignancies: A review

Tang, H., Li, Y. X., Lian, J. J., Ng, H.-Y., & Wang, S. S. Y. (2024) · Tumori Journal · doi:10.1177/03008916241261484 · Cited by 5

TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda

Nzitakera, A., Uwamariya, D., Kato, H., Surwumwe, J. B., Mbonigaba, A., Ndoricyimpaye, E. L., Uwamungu, S., Manirakiza, F., Ndayisaba, M. C., Ntakirutimana, G., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13009-8 · Cited by 5

Consensus molecular subtyping of colorectal carcinoma brain metastases reveals a metabolic signature associated with poor patient survival

Irmer, B., Wlochowitz, D., Krekeler, C., Richter, K. M., Chandrabalan, S., Bayerlová, M., Wolff, A., Lenz, G., Conradi, L., Schildhaus, H., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13748 · Cited by 5

CPDR: An R Package of Recommending Personalized Drugs for Cancer Patients by Reversing the Individual’s Disease-Related Signature

Chen, R., Wang, X., Deng, X., Chen, L., Liu, Z., & Li, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.904909 · Cited by 5

Biomarkers for anti‑vascular endothelial growth factor drugs

Kuriyama, S., Yamada, T., Matsuda, A., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Miyasaka, T., Yokoyama, Y., Shinji, S., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13583 · Cited by 7

Impact of Age of Onset on Survival after Hepatectomy for Patients with Colorectal Cancer Liver Metastasis: A Real-World Single-Center Experience

Wang, H., Wang, L., Jin, K., Bao, Q., Li, J., Ge, S., Wang, K., & Xing, B. (2022) · Current Oncology · doi:10.3390/curroncol29110666 · Cited by 5

Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer

Zhou, W., He, M.-M., Wang, F., Xu, R., Wang, F., & Zhao, Q. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00412-w · Cited by 5

Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study

Cayún, J. P., Cerpa, L. C., Colombo, A., Cáceres, D., Leal, J. L., Reyes, F., Gutiérrez-Cáceres, C., Calfunao, S., Varela, N., & Quiñones, L. A. (2024) · Current Oncology · doi:10.3390/curroncol31010018 · Cited by 6

Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Zhao, R., Han, M., Lin, S., Lin, Z., Yu, M., Zhang, B., Ma, L., Li, D., & Peng, L. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2380513 · Cited by 5

Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1

Rajarajan, S., Anupama, C. E., Jose, B., Correa, M., Sengupta, S., & Prabhu, J. S. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2128 · Cited by 5

Discovery and Opportunities With Integrative Analytics Using Multiple‐Omics Data

Athreya, A. P., & Lazaridis, K. N. (2021) · Hepatology · doi:10.1002/hep.31733 · Cited by 5

Investigation of clinicopathological characters and gene expression features in colorectal signet‑ring cell carcinoma utilizing CMS classification

Tajiri, K., Sudo, T., Ishi, K., Kawahara, A., Nagasu, S., Shimomura, S., Yuge, K., Katagiri, M., Yomoda, T., Fujiyoshi, K., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2260 · Cited by 5

SSCS: A Stage Supervised Subtyping System for Colorectal Cancer

Zhao, L., & Pan, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9121815 · Cited by 5

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Alig, A. H. S., Heinemann, V., Geißler, M., von Weikersthal, L. F., Decker, T. W., Heinrich, K., Held, S., Weiss, L., Fischer, L. E., Moosmann, N., et al. (2022) · Cancers · doi:10.3390/cancers14030526 · Cited by 5

Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

Mini, E., Landini, I., Paolo, A. D., Ravegnini, G., Saponara, S., Frosini, M., Lapucci, A., & Nobili, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00002-0 · Cited by 5

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201

Takahashi, S. I., Ouchi, K., Sakamoto, Y., Mori, T., Shimodaira, H., Takahashi, M., Ohori, H., Kudo, C., Takahashi, Y., Imai, H., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-862 · Cited by 5

Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway

Kawaguchi, T., Okamoto, K., Fujimoto, S., Bando, M., Wada, H., Miyamoto, H., Sato, Y., Muguruma, N., Horimoto, K., & Takayama, T. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02052-0 · Cited by 5

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5

Poor-prognosis young-onset colorectal cancer is defined by the mesenchymal subtype and can be predicted by integrating molecular and histopathological characteristics

Ke, J., Li, Y., Qi, L., Li, X., Wang, W., ten Hoorn, S., Zhu, Y., Huang, H., Gao, F., Vermeulen, L., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100181 · Cited by 4

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Stahler, A., Modest, D. P., Stintzing, S., Borelli, B., Keller, T., Held, S., von Weikersthal, L. F., Müller, L., Graeven, U., Decker, T. W., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00596 · Cited by 4

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer

Yang, M., Nebozhyn, M., Schell, M. J., Gandhi, N. S., Pflieger, L. T., Loboda, A. P., Pledger, W. J., Soundararajan, R., Maurin, M. M., Wang, H., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13829-2 · Cited by 4

Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis

Dai, Z., Peng, X., Guo, Y., Shen, X., Ding, W., Fu, J., Liang, Z., & Song, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04070-6 · Cited by 4

Immunotherapy in Colorectal Cancer: A Review

Colombo, A., Gebbia, V., & Porretto, C. M. (2024) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00008 · Cited by 4

KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry‐based subtyping

Rao, J., Sinn, M., Pelzer, U., Riess, H. B., Oettle, H., Demir, İ. E., Friess, H., Jäger, C., Steiger, K., & Muckenhuber, A. (2024) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.12377 · Cited by 4

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

Airoldi, M., Bartolini, M., Fazio, R., Farinatti, S., Daprà, V., Santoro, A., & Puccini, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01601-x · Cited by 5

Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis

Wu, Q., Wang, H., Zhang, S., Zeng, Y., Yang, W., Pan, W., Hong, G., & Gao, W. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02707-x · Cited by 4

The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

Antoniotti, C., Ongaro, E., Falcone, A., & Cremolini, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082298 · Cited by 4

Redefining colorectal cancer classification and clinical stratification through a single-cell atlasPreprint

Khaliq, A. M., Kurt, Z., Grunvald, M. W., Erdoğan, C., Turgut, S. S., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429256 · Cited by 4

New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People

Bayat, A., Sharafshah, A., Sefat, F., Rahimzadegan, M., Raad, M., & Lewandrowski, K. (2024) · Current Aging Science · doi:10.2174/0118746098348122241024061610 · Cited by 4

Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy

Iglesias, M., Badia-Ramentol, J., Martínez‐Ciarpaglini, C., Linares, J., Tarazona, N., Mulet-Margalef, N., Tornero-Piñero, P., Sallent-Aragay, A., Recort-Bascuas, A., Gibert, J., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-336804 · Cited by 3

Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target

Chen, S., Jiang, Z., Song, W., Lu, C., Lin, Y., Xu, S. S., Xie, K., Wan, L., & Yuan, X. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03918-8 · Cited by 3

Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer

Mochizuki, K., Kudo, S., Kato, K., Kudo, K., Ogawa, Y., Kouyama, Y., Takashina, Y., Ichimasa, K., Tobo, T., Toshima, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273566 · Cited by 3

Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients

Oki, E., Shinto, E., Shimokawa, M., Yamaguchi, S., Ishiguro, M., Hasegawa, S., Takii, Y., Ishida, H., Kusumoto, T., Morita, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-09088-6 · Cited by 3

Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer

Bianchi, A. S., Alfonso, P. G., Geißler, M., Köhne, C., Peeters, M., Price, T. J., Valladares‐Ayerbes, M., Zhang, Y., Burdon, P., Taı̈eb, J., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.05.007 · Cited by 3

Linking Genotype to Phenotype: Bench to Bedside

George, S., & Bertagnolli, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0027 · Cited by 3

Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer

Arai, H., Millstein, J., Loupakis, F., Stintzing, S., Wang, J., Battaglin, F., Kawanishi, N., Jayachandran, P., Soni, S., Zhang, W., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.048 · Cited by 2

Microbial interactions induce the mutational signature of mismatch repair deficiency in colorectal cancer and associated with EPPK1 mutations

Hu, D., Zhao, J., Wu, M., Zhou, Y., Lyu, B., Xu, C., Huang, C., Su, Z., Zhang, H., Guo, J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217807 · Cited by 2

Cancer evolution and multi-omic profile of relapsed colorectal liver metastases after treatment

Tomás, L., Raschzok, N., Blanc, E., Gallardo‐Gómez, M., Menne, A., Astrahantseff, K., Chiara, L. D., Geisel, D., Pratschke, J., Modest, D. P., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01614-0 · Cited by 2

Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study

Yang, T., Chen, H., Bo‐Wen, L., Kim, T. W., Kim, J. G., Ahn, J. B., Lee, M. A., Lin, J., Ho, G. F., Anh, L. T., et al. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13920 · Cited by 2

Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved

Ioffe, D., McSweeny, M. J., & Hall, M. J. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770385 · Cited by 2

NanoCMSer : a consensus molecular subtype stratification tool for fresh‐frozen and paraffin‐embedded colorectal cancer samples

Torang, A., van de Weerd, S., Lammers, V., van Hooff, S. R., van den Berg, I., van den Bergh, S., Koopman, M., IJzermans, J. N. M., Roodhart, J. M. L., Köster, J., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13781 · Cited by 2

Evaluation of a novel surrogate panel for classifying human colorectal carcinomas according to consensus molecular subtypes

Mani, P., Mehra, L., Deepak, R. K., Tiwari, A., Kumar, S., Chethan, R., Dutta, R., Dash, N. R., Yadav, R., Deo, S. V. S., et al. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105840 · Cited by 2

The heterogeneity of genomic alterations, metastatic patterns and immune microenvironment in metastatic ovarian cancer originating from colorectal cancer

Chen, C., Wang, J., Sun, B., Zheng, Y., Ge, X., Gong, Z., Gu, H., Zhang, Z., Zhu, A., Shao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593439 · Cited by 2

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

Battaglin, F., O’Neil, B. H., Stintzing, S., Ou, F., Zemla, T., Niedzwiecki, D., Innocenti, F., Höchster, H. S., von Weikersthal, L. F., Decker, T. W., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115694 · Cited by 2

Consensus molecular subtyping of colorectal cancer by immunohistochemistry, an imperative for a resource limited setting

Abdulkareem, F. B., Khramtsova, G. F., Odukoya, L. A., Badmos, K. B., Adedokun, T., Rotimi, O., Ibraheem, A. F., Khramtsov, A., Sveen, L., Hurley, I. W., et al. (2021) · Nigerian Journal of Gastroenterology and Hepatology · doi:10.4103/njgh.njgh_1_22 · Cited by 2

Coffee Consumption and Colorectal Cancer Prognosis

Tan, I. T., & Lin, A. Y. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.8485 · Cited by 2

Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapiesPreprint

Yazdani, A., Yazdani, A., Méndez-Giráldez, R., Pillonetto, G., Samiei, E., Hadi, R., Lenz, H., Venook, A. P., Samiei, A., Nixon, A. B., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4047331/v1 · Cited by 2

Molecular Oncology in Management of Colorectal Cancer

Vemala, R. N. G., Katti, S. V., Sirohi, B., Manikandan, D., & Nandakumar, G. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01289-6 · Cited by 2

A Super‐Enhancer‐Related Ferroptosis Signature Predicts Survival and Immune Microenvironment in Colon Cancer Based on Bioinformatics Analyses and Experimental Validation

Wan, L., Li, J. J., & Xie, X. (2025) · IET Systems Biology · doi:10.1049/syb2.70043 · Cited by 1

Oncogenicity and Therapeutic Implications of Molecular Biomarkers in Colorectal Carcinoma

Evans, M. G., & Hechtman, J. F. (2026) · Surgical pathology clinics · doi:10.1016/j.path.2026.01.010 · Cited by 1

Comprehensive analysis of first-line, maintenance, and subsequent-line therapies for metastatic colorectal cancer: a systematic review, meta-analysis, and network meta-analysis

Jiang, Y., Zhao, M., & Wang, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004152 · Cited by 1

Reduced YTHDF2 inhibits PD-L1 expression by stabilizing m6A-containing SPOP mRNA in colorectal cancer

Xu, X., Cai, C. H., Zhao, R., Xie, J., Liu, H., Xie, B., Lou, J., Wang, H., Wu, X., Han, W., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08615-2 · Cited by 1

Molecular Determinants of Gastrointestinal Cancers

Battaglin, F., Randon, G., Raimondi, A., Pagani, F., Arai, H., Pietrantonio, F., & Lenz, H. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.026 · Cited by 1

Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis

ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Lenz, H., Ou, F., Venook, A. P., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3511 · Cited by 51

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Mooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P. S., Price, T. J., Townsend, A. R., Hardingham, J. E., Buchanan, D. D., Williams, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy410 · Cited by 144

Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial

Mooi, J. K., Wirapati, P., Asher, R., Lee, C., Savas, P. S., Price, T. J., Tejpar, S., Mariadason, J. M., & Tebbutt, N. C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.006 · Cited by 1

The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer.

Okita, A., Takahashi, S. I., Ouchi, K., Inoue, M., Yamada, Y., & Ishioka, C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.736 · Cited by 1